Human Genome Sciences Inc. (NYSE: HGSI) reversed year ago losses of 39 cents per share to post a profit of 85 cents per share for the first quarter due to sales of its anthrax treatment sending the stock price soaring 80 cents to close at $2.19.
Human Genome Reverses Losses
April 30, 2009 at 16:55 PM EDT
